SUN PHARMACEUTICAL INDUSTRIES LTD. Q1 FY26 Results
SUNPHARMAQ1 FY26 ResultsAnnounced 31 Jul 2025, 02:31 pm| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 13.9K | 6.9% |
| Total Income | 14.3K | 5.5% |
| Expenditure | 10.3K | 3.7% |
| PBT | 3.2K | 2.5% |
| Net Profit | 2.3K | 6.5% |
| OPM | 25.15% | 0.74pp |
| NPM | 16.02% | 0.15pp |
| EPS | 9.50 | 5.6% |
Sun Pharmaceutical Reports Q1 FY 2025-26 Financial Results with 14.72% Increase in Profit Before Exceptional Items and Tax
31 Jul 2025 · 31 Jul 2025, 02:37 pm
Summary
Sun Pharmaceutical Industries Limited has reported its Q1 FY 2025-26 financial results with a 14.72% increase in profit before exceptional items and tax. The company's board has approved the financial results and changes in the composition of the board committees.
Key Highlights
- 1
14.72% increase in profit before exceptional items and tax
- 2
Changes in the composition of the board committees
- 3
Approval of the Unaudited Standalone and Consolidated Financial Results for Q1 of FY 2025-26
Management Comments
Dilip Shanghvi
Appointed as a member of the Nomination and Remuneration Committee and Corporate Governance and ESG Committee
Sudhir Valia
Ceases to be a member of the Nomination and Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee, and Corporate Social Responsibility Committee upon his retirement at the conclusion of the 33rd Annual General Meeting
Aalok Shanghvi
Appointed as a member of the Stakeholders Relationship Committee, Risk Management Committee, and Corporate Governance and ESG Committee
Kirti Ganorkar
Appointed as a member of the Nomination and Remuneration Committee and Corporate Governance and ESG Committee, replacing Mr. Dilip Shanghvi in the latter from 1 September 2025, subject to shareholder approval
Vidhi Shanghvi
Appointed as a member of the Corporate Social Responsibility Committee
Informational and educational content only. Not investment advice.